Miracle Leaf® qualifying-conditions guide

Medical Marijuana for Hepatitis C

Viral infection that causes inflammation and progressive liver damage. Cannabis has insufficient evidence as a treatment for hepatitis C itself, though it is qualifying in several state programs for symptom management during interferon-based regimens, which are now largely obsolete.

Reviewed by Miracle Leaf® Editorial Team

Last reviewed 2026-08-04

Book Evaluation Call (833) LEGAL-MJ

NASEM evidence levelLimitedICD-10: B18.2

What is Hepatitis C?

Hepatitis C is a bloodborne viral infection that causes inflammation and, untreated, progressive scarring of the liver leading to cirrhosis and hepatocellular carcinoma. Since the introduction of direct-acting antiviral (DAA) therapies in 2014, hepatitis C is now curable in over 95% of patients with an 8-to-12-week oral regimen, displacing the older interferon- and ribavirin-based treatments.

Does cannabis help Hepatitis C?

Evidence for cannabis as a treatment for hepatitis C is insufficient. Historically, the qualifying-condition basis was symptom management (nausea, anorexia, fatigue, depression) during the burdensome side-effect profile of interferon-based therapy, which is now obsolete in standard practice.

Hepatitis C remains a qualifying condition under medical cannabis programs in approximately 20 states. The clinical utility of this designation has substantially diminished post-DAA. Patients should pursue evidence-based DAA therapy, which is highly effective, well-tolerated, and curative for most chronic HCV infections.

Eligibility

State eligibility for Hepatitis C

Whether this condition is listed varies by state program. A Miracle Leaf® physician determines eligibility during your evaluation.

State-by-state eligibility for Hepatitis C: whether the condition qualifies under Florida, Georgia, and Texas medical cannabis programs.
State	Qualifies?	Program
Florida	Not listed	Florida OMMU
Georgia	Not listed	Georgia DPH Medical Cannabis Registry
Texas	Not listed	Texas Compassionate Use Program

This table covers Florida, Georgia, and Texas, the three states where Miracle Leaf® operates clinics. Miracle Leaf® also serves patients by telehealth in 22 more states, where qualifying conditions are set by each state's own program. See the telehealth state guides for eligibility where you live.

Outside Florida, Georgia, or Texas?

Telehealth visits are available in 22 states. See telehealth states

Common questions

Frequently asked questions

Does cannabis treat hepatitis C?

No. Cannabis is not a treatment for hepatitis C virus (HCV) infection. Modern direct-acting antiviral (DAA) regimens cure over 95% of patients in 8-12 weeks of oral therapy. Cannabis evidence for hepatitis C is insufficient.

Is any cannabis-derived product FDA-approved for hepatitis C?

No. No cannabis or cannabinoid product is FDA-approved for hepatitis C. The FDA-approved DAA regimens (including combinations such as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) have transformed hepatitis C into a curable infection.

Why do some state medical-cannabis programs list hepatitis C as a qualifying condition?

Most enumerations date to the interferon era, when patients on interferon-plus-ribavirin regimens experienced severe nausea, fatigue, depression, and anorexia for which cannabis offered symptomatic relief. Since DAA therapies displaced interferon (post-2014), the practical rationale for cannabis-for-hepatitis-C has narrowed substantially.

Yes. Patients with advanced liver disease (cirrhosis) should approach cannabis cautiously: cannabinoids are metabolized hepatically and can interact with antiviral medications and other agents commonly prescribed in liver disease. Smoking compounds known cardiopulmonary risk in patients who may already have advanced liver-disease comorbidities. Disclose cannabis use to the hepatology team.

Sources and citations

Ready to talk with a Miracle Leaf® physician?

Book Evaluation Call (833) LEGAL-MJ Shop Now

Reviewed by Miracle Leaf® Editorial Team. This page summarizes current peer-reviewed evidence and federal guidance and is updated when the source documents materially change.